Ketamine Troches vs. Intramuscular Injection: Key Differences

Two Routes Beyond the Vein

When patients and providers look beyond intravenous ketamine, two alternatives dominate: sublingual troches and intramuscular (IM) injection. Both offer higher bioavailability than oral swallowing. Understanding how troche absorption works helps explain why bioavailability differs so much between routes, and both can be administered outside the strict IV clinic infrastructure — though IM still requires a clinician or trained support. Here's how they compare across the factors that matter most to patients.

How Intramuscular Ketamine Works

Intramuscular injection delivers ketamine directly into muscle tissue, from which it absorbs into the bloodstream via surrounding capillaries. The deltoid (shoulder) and vastus lateralis (thigh) are the most common injection sites. IM absorption is not as instantaneous as IV, but it is significantly faster and more complete than sublingual absorption.

IM Bioavailability

Intramuscular ketamine has a bioavailability of approximately 93 percent — nearly as complete as IV, far superior to oral or sublingual routes. For a cost perspective on these different approaches, see our cost comparison. This means a 35 mg IM dose delivers approximately 32.5 mg of ketamine to systemic circulation, with predictable pharmacokinetics.

IM Onset and Duration

• Onset: 5 to 15 minutes after injection
• Peak: 15 to 30 minutes
• Duration: 30 to 60 minutes of significant effects, with return to near-baseline within 90 to 120 minutes

IM sessions are typically shorter and more intense than troche sessions, with a faster climb and faster resolution.

Absorption Comparison: IM vs. Troche

The troche's longer duration and more gradual onset can be therapeutically valuable — many patients and clinicians find the extended window allows more time for emotional processing and integration than the rapid IM experience. The IM route's near-complete bioavailability means dosing is more precise and predictable.

Setting: Where Each Is Used

IM Ketamine

IM administration requires someone to give the injection, which means at minimum a trained clinician or, in some protocols, a trained family member. This typically places IM ketamine in:

• Ketamine clinics: Many clinics offer both IV and IM options; IM tends to cost less and requires less equipment
• Psychiatrist or physician offices: Some prescribers administer IM in-office
• Home with trained support: In some protocols (particularly for palliative care or chronic pain), caregivers are trained to administer IM injections at home

IM cannot currently be self-administered (without training) and is therefore inherently less autonomous than troche therapy.

Troches

As discussed throughout this site, troches are designed for home use by the patient without any injection or clinical procedure. This is their primary practical advantage: patient autonomy and elimination of clinic visits.

Cost: IM vs. Troche

IM Ketamine Clinic Costs

IM sessions at ketamine clinics typically cost between $250 and $500 per session — somewhat less than IV infusions, which require more equipment and longer staff time, but still a significant per-session cost. A standard 6-session acute course costs $1,500 to $3,000.

Troche Costs

A month of troche therapy (4 to 8 troches at typical maintenance dosing) costs approximately $150 to $400 including compounding pharmacy fees, with additional provider visit costs. The lower per-session cost makes troches substantially more affordable for ongoing maintenance.

Clinical Efficacy

IM Evidence Base

IM ketamine is well-studied, with numerous clinical trials and retrospective analyses demonstrating rapid antidepressant effects comparable to IV administration. Some researchers argue IM produces slightly different pharmacokinetics (faster initial peak, shorter duration) that may have a distinct effect on the therapeutic experience compared to IV, though both routes are effective.

Troche Evidence

The evidence base for troches is smaller but growing. Clinical data from outpatient practices and a modest number of published studies support efficacy for treatment-resistant depression and chronic pain in appropriate patients. The variability in troche bioavailability makes direct dose-to-dose comparison with IM more complex.

For patients who have not responded to oral antidepressants and want ketamine therapy, the current evidence suggests starting with IV or IM for acute treatment, then potentially transitioning to troches for maintenance.

Patient Experience Differences

Needle Aversion

For patients with significant needle phobia, troches offer an obvious advantage: no injection. IM administration requires a needle penetration into muscle, which is more painful than IV access (due to the volume of fluid being injected and the nature of intramuscular injection) and can cause localized soreness lasting 1 to 2 days.

Intensity and Character of Experience

• IM: Faster onset and higher bioavailability typically produce more intense, shorter experiences. Patients often describe IM sessions as more "telescoped" — a rapid rise, intense peak, and relatively quick resolution.
• Troches: The gentler, longer onset and gradual come-down are often described as more comfortable and allowing more time to process emotional content.

Neither profile is inherently superior. Patient preference and therapeutic goals guide the choice.

Injection Site Reactions

IM ketamine can cause localized pain, bruising, or muscle soreness at the injection site. These are minor and self-limiting but absent in troche therapy. Repeat injections at the same site can cause tissue irritation; clinical providers rotate injection sites.

Safety Considerations

Both IM and troche ketamine carry similar systemic safety considerations — cardiovascular effects (blood pressure and heart rate elevation), risk of psychological distress during the session, and the potential for adverse effects in predisposed individuals.

The key safety difference lies in monitoring:

• IM in clinic: Administered by trained staff with monitoring equipment; adverse events can be managed immediately
• IM at home: Requires trained administration, and emergency response protocols, but lacks continuous monitoring
• Troches at home: Patient-managed, relies on preparation, safety protocols, and a support person

For patients with significant cardiovascular risk or a history of adverse reactions to ketamine, clinical administration (IV or IM in a monitored setting) is safer than home-based troche therapy.

When IM Might Be Preferred Over Troches

• Acute treatment courses: When rapid, reliable response is needed, IM's near-complete bioavailability makes dosing more predictable.
• Patients who cannot maintain sublingual/buccal position: Some patients have difficulty keeping troches in place due to dry mouth, movement disorders, or anatomy.
• Pain management requiring reliable, rapid analgesia: For patients who need consistent and rapid pain relief, IM's predictable onset may be superior.
• Provider preference: Some clinic-based providers prefer IM for its manageability and simpler monitoring protocols compared to IV.

When Troches Might Be Preferred Over IM

• Maintenance therapy: For long-term maintenance after an initial acute course, the cost and logistical simplicity of troches are compelling.
• Geographic access: Patients far from clinics cannot easily access IM or IV options.
• Needle aversion: For patients with significant fear of injections, troches remove a barrier to treatment.
• Patient autonomy: Patients who value the ability to conduct treatment on their own schedule and in their own environment often find troches more sustainable long-term.

Key Takeaways

• IM ketamine has ~93% bioavailability versus 20-30% for troches; IM sessions are shorter and more intense.
• IM requires clinical or trained administration; troches are patient-managed at home.
• IM costs $250 to $500 per session; troches average $150 to $400 per month.
• Both routes are clinically effective; the choice depends on condition severity, patient preferences, and access.
• Many patients use IM or IV for acute treatment and troches for maintenance.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• Healthcare.gov: Understanding Costs — Federal marketplace resource explaining insurance terminology and out-of-pocket healthcare costs